-
Mashup Score: 18
Voydeya (danicopan) has been approved in the European Union (EU) as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia. 1 Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant extravascular haemolysis
Source: www.astrazeneca.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 9Working at Alexion - 13 day(s) ago
Browse available job openings at Alexion
Source: careers.alexion.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 8Rare Connections in NMOSD - 21 day(s) ago
We asked three people with NMOSD to write a letter about their journey. See what happens when they exchange letters and experience each other’s stories for t…
Source: www.youtube.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 6
We are committed to innovation in clinical trials which puts patients at the heart of our research. Learn more here.
Source: www.astrazeneca.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 9Working at Alexion - 1 month(s) ago
Browse available job openings at Alexion
Source: careers.alexion.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 2Homepage - World Kidney Day 2024 - 2 month(s) ago
World Kidney DayRaising awareness of theimportance of our kidneyswho we are find out more find out more find out more find out more Worldwide activities Around the globe, people will be coming together to mark World Kidney Day. How will you be celebrating? Let us know by posting information about your activity on our activity map! […]
Source: www.worldkidneyday.orgCategories: General Medicine News, PayerTweet
-
Mashup Score: 8Driving health equity for the rare disease community - 2 month(s) ago
Learn more about the unique challenges faced by patients living with rare diseases and how we are working to advance health equity for this community.
Source: www.astrazeneca.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 8Homepage - 3 month(s) ago
When you’re here, you’re part of a globally connected community committed to eliminating the challenges of rare disease. Global Genes is committed to providing information, resources and connections to all communities affected by rare diseases. The RARE Drug Development Symposium, hosted by Global Genes and the Orphan Disease Center of the University of Pennsylvania, equips advocates with the knowledge, skills and connections they need to advance therapy development for their communities. This year’s
Source: globalgenes.orgCategories: General Medicine News, PayerTweet
-
Mashup Score: 7Driving health equity for the rare disease community - 3 month(s) ago
Learn more about the unique challenges faced by patients living with rare diseases and how we are working to advance health equity for this community.
Source: www.astrazeneca.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 2Voydeya (danicopan) granted first-ever regulatory approval in Japan for adults with PNH to be used in combination with C5 inhibitor therapy - 3 month(s) ago
Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal hae moglobinuria (PNH). It is indicated in Japan in combination with C5 inhibitor therapy when patients have had an insufficient response to such C5 inhibitors. 1 Voydeya is a first-in-class, oral, Factor D inhibitor developed as add-on to proven standard-of-care Ultomiris or Soliris to address the needs of the subset of patients (approximately 10-20%) with PNH who experience clinically significant extravascular
Source: www.astrazeneca.comCategories: General Medicine News, PayerTweet
For Medical Media/Investors: Today, we’re excited to announce that the European Commission has granted a marketing authorisation for our latest medicine in the field of paroxysmal nocturnal haemoglobinuria. Learn more: https://t.co/y5uDDEZxbX https://t.co/UK67Me7fAA